Compare ARK Genomic Revolution ETF (ARKG) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? ARK Genomic Revolution ETF trades at $44.62, while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.16. Which is the better fit depends on your goals.
| ARKG | QQQE | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $44.55 | $122.72 |
52-Week Low | $24.02 | $96.06 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
QQQE trades at $123.25, up 0.9% on the day, with a bullish technical signal from moving averages but a neutral oscillator reading. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk in top holdings like tech giants. Recent news highlights its appeal as a defensive play amid the Nasdaq rally, with SpaceX's imminent inclusion potentially driving inflows.
The outlook remains positive given structural diversification benefits and growth exposure, though overbought RSI levels near 79 suggest near-term caution. Risks include market volatility and tech sector sensitivity, but analyst sentiment favors QQQE over market-cap-weighted peers for balanced Nasdaq participation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
